Background: We examined the physicochemical properties of IgD-type M protein from 10 patients with IgD-type M protein and those with other types of M protein.
Methods: Identification of the L-chain type by routine methods (Immunoelectrophoresis: IEP, Immunofixation electrophoresis; IFE), detection of IgD-IgG complexes and the changes in the mobility by treatment with acid.
Results: Identification of the L-chain type by both IEP and IFE was impossible. Only one patient revealed the possibility of IgD-IgG complex bands in 6 of the 10 samples. Changes in mobility by treatment with acid were observed in 8 of the 10 samples of IgD-type M protein.
Conclusions: These abnormalities are caused by the primary structure of IgD, which may be related to the well-known weak reactivity with L-chain antibody.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7754/Clin.Lab.2024.240515 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[BCMA chimeric antigen receptor T cells therapy re-treatment of a patient with recurrent/refractory IgD multiple myeloma: A case report and literature review].
Zhonghua Xue Ye Xue Za Zhi
October 2024
Department of Hematology, The Myeloma & Lymphoma Center, The Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai 200003, China.
Multiple myeloma (MM) is a malignant plasma cell disease that currently cannot be cured. Several new drugs have continuously been introduced in the recent years. New drugs targeting B-cell maturation antigen (BCMA) have greatly improved the efficacy and prognosis of MM compared with traditional treatments.
View Article and Find Full Text PDFBackground: We examined the physicochemical properties of IgD-type M protein from 10 patients with IgD-type M protein and those with other types of M protein.
Methods: Identification of the L-chain type by routine methods (Immunoelectrophoresis: IEP, Immunofixation electrophoresis; IFE), detection of IgD-IgG complexes and the changes in the mobility by treatment with acid.
Results: Identification of the L-chain type by both IEP and IFE was impossible.
Withdrawal from Hemodialysis in a Patient with IgD Type Multiple Myeloma: A Case-based Review.
Acta Med Okayama
April 2023
Department of Internal Medicine, Kochi Prefectural Hata-Kenmin Hospital.
Article Synopsis
- Several case reports indicate that patients with IgD multiple myeloma (MM) may successfully stop hemodialysis, although specific predictive factors have not been established.
- A 57-year-old Japanese woman with renal issues from IgD-λ multiple myeloma underwent bortezomib-based chemotherapy and was able to withdraw from hemodialysis after 50 days.
- This review suggests that younger age and starting bortezomib-based treatment early could be key indicators for successfully stopping hemodialysis in similar patients.
[Effects of extramedullary disease on patients with newly diagnosed multiple myeloma].
Zhonghua Xue Ye Xue Za Zhi
January 2023
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
To summarize the characteristics of patients with newly diagnosed multiple myeloma (NDMM) admitted at Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine. We compared the clinical characteristics and prognoses among patients with non-extramedullary disease (EMD), bone-related extramedullary (EM-B) disease, and extraosseous extramedullary (EM-E) disease and further explored the effects of autologous hematopoietic stem cell transplantation (ASCT) for EMD. From January 2015 to January 2022, data of 114 patients (22%) with EMD out of 515 patients with NDMM were retrospectively analyzed; 91 (18%) and 23 (4%) patients comprised the EM-B and EM-E groups, respectively.
View Article and Find Full Text PDFInterstitial Granulomatous Dermatitis as an Adverse Reaction to Vedolizumab.
Cutis
March 2022
Ms. Beuerlein is from the Wake Forest School of Medicine, Winston-Salem, North Carolina. Drs. Martin and Strowd are from the Department of Dermatology, Wake Forest Baptist Health, Winston-Salem.
A 61-year-old woman with a medical history of ulcerative colitis (UC) developed an erythematous, mildly pruritic, maculopapular rash that was histologically consistent with reactive granulomatous dermatitis (RGD) with interstitial granulomatous dermatitis (IGD)-type features 1 week after vedolizumab infusion. Awareness of this complication is key to enhanced recognition and appropriate management as use of this medication becomes more prevalent.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!